5505 MOREHOUSE DRIVE, SAN DIEGO, CA
Stockholders Approve Amendment to 2024 Equity Incentive Plan
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Other Events
Director Resignation - Diego Miralles Steps Down; CFO Departure - Thad Huston
Artiva Biotherapeutics Enters Underwriting Agreement for 23.87M Shares
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Reports Full Year 2025 Financial Results and Recent Business Highlights
CFO Appointment - Thad Huston Named Chief Financial Officer
Q2
Q1
Amended Annual Report
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus
S-1MEF